Melanoma VA Claim: PACT Act Presumptive + Service Connection (2026)

PACT Act Presumptive for Melanoma

The Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022 is the most significant expansion of VA benefits in decades. For cancer claims, the PACT Act created a powerful presumption: veterans who served in covered locations during covered time periods and who develop certain cancers — including melanoma — do not need to prove that their service caused the cancer. The presumption does it for them.

Under 38 CFR §§ 3.320 and 3.323 (as amended by the PACT Act), VA presumes that cancers in qualifying veterans are connected to toxic exposure from burn pits, airborne hazards, particulate matter, and other environmental exposures during covered service. Melanoma — classified as a malignant neoplasm of the skin — is included in the covered cancers under this framework.

The PACT Act's presumptive framework for cancers draws from the principle that burn pits and airborne hazards in deployed environments produce carcinogenic compounds — including polycyclic aromatic hydrocarbons (PAHs), benzene, volatile organic compounds, and heavy metals — many of which are established or probable human carcinogens. The science connecting these exposures to cancer, including skin cancers, is why Congress included melanoma in the covered list.

It is important to understand that even before the PACT Act, VA recognized that certain toxic exposures caused cancer. Agent Orange presumptives date back decades. What the PACT Act did was dramatically expand coverage to Gulf War era and post-9/11 veterans, and to cancers — including melanoma — that were not previously covered by other presumptives.

Who Qualifies for the PACT Act Melanoma Presumptive

Eligibility for the PACT Act cancer presumptive requires service in a covered location during a covered period. VA tracks qualifying service through a combination of deployment records, unit records, and the Airborne Hazards and Open Burn Pit Registry.

Covered Locations and Time Periods

Veterans who served in these locations for any length of time — even temporary duty (TDY) — may qualify. You do not need to have served the entire deployment period; a single rotation qualifies. Service in multiple locations at different times is additive — each qualifying period counts.

Documenting Your Qualifying Service

Your DD-214 is the primary service document, but it may not reflect every temporary deployment or short-term assignment. Additional documentation sources include:

• Service Personnel Records (DA Form 201 File / OMPF) — orders for each deployment, TDY, or permanent change of station to covered locations
• Unit records and deployment orders — orders may list specific countries or bases
• Airborne Hazards and Open Burn Pit Registry — VA's registry documents veterans who served near burn pits; enrollment is not required to claim benefits but helps document exposure
• Buddy statements — fellow service members who can confirm your presence in covered locations
• Awards and citations — campaign medals (Afghanistan Campaign Medal, Iraq Campaign Medal, Global War on Terrorism Expeditionary Medal) independently confirm qualifying service in covered areas

Direct Service Connection via Occupational Sun Exposure

Not every veteran with melanoma will qualify for the PACT Act presumptive — either because their service dates or locations don't meet the criteria, or because their melanoma was diagnosed decades before the PACT Act's passage. For these veterans, direct service connection via occupational UV exposure is the path forward.

Military service creates documented occupational UV exposure risks that are not present in typical civilian employment. Many MOSs require sustained outdoor duty — often in high-UV environments — without adequate sun protection. The medical literature on occupational UV exposure and melanoma risk is extensive: high cumulative UV exposure is a well-established risk factor for melanoma.

Outdoor Military Occupations with High UV Exposure

• Infantry (11-series) — Extended foot patrols, static positions, and field training in full sun, often in arid high-UV environments (Southwest Asia, California, Texas, Arizona training areas)
• Armor and Cavalry — Tank commanders and scouts spend significant time exposed outside vehicles; vehicle hatches and TC positions provide no UV protection
• Combat Engineers — Field construction, mine clearance, and route clearance operations in direct sun
• Aviation (aviators and crew chiefs) — Cockpit and flight deck UV exposure is documented; aircraft windshields do not block all UV radiation
• Special Forces / Rangers — Extended field operations in high-UV regions; patrol schedules often include midday hours
• Navy surface warfare — Deck operations, underway watch, and port duty in direct sun, often in tropical or equatorial regions with very high UV indices
• Marines (0300s, combat MOSs) — Field training at Twentynine Palms, Pendleton, and deployed environments with intense solar radiation
• Military Police and Security Forces — Outdoor post duty, gate guard, and patrol in all weather, including full summer sun

Direct service connection for melanoma requires three elements under 38 CFR § 3.303: (1) a current diagnosis of melanoma; (2) evidence of an in-service event, injury, or disease — in this case, the pattern of sustained occupational UV exposure during service; and (3) a medical nexus connecting the two. For direct service connection via UV exposure, that nexus typically comes from a dermatologist's or oncologist's opinion documenting the causal relationship.

What a Nexus Letter for Melanoma Must Address

• The provider's credentials and specialty (dermatology or oncology strongly preferred)
• Records reviewed: service treatment records, MOS history, deployment records, current diagnosis and staging
• The veteran's specific outdoor duty history and estimated UV exposure hours based on MOS and duty locations
• Medical literature supporting the connection between cumulative occupational UV exposure and melanoma risk
• The anatomical location of the melanoma (sun-exposed areas like face, neck, forearms, back of hands — more compelling for UV causation)
• Whether the veteran had other risk factors (family history, photosensitive skin type) and an opinion that service UV exposure was at least as likely as not a substantial contributing factor
• The specific nexus statement: "at least as likely as not" (50% or greater probability) that the melanoma was caused by or materially contributed to by military service

Veterans pursuing direct service connection should understand that the standard is "at least as likely as not" — not certainty. A well-documented nexus letter from a qualified specialist tying the veteran's specific military UV exposure history to the melanoma diagnosis meets this standard for most claims.

DC 7833: How VA Rates Melanoma

VA rates melanoma under Diagnostic Code 7833 — Malignant neoplasms of the skin — in 38 CFR Part 4, Schedule for Rating Disabilities, under the skin conditions section.

The 100% rating during active treatment is categorical — it applies regardless of stage (Stage I through Stage IV), regardless of treatment type, and regardless of whether the melanoma is localized or has spread. The key trigger is active ongoing treatment.

Under 38 CFR § 4.117, Note (a) to DC 7833: "A rating of 100 percent shall be assigned as of the date of histologic diagnosis [of a malignant neoplasm] if it requires continuous medication, treatment, or supervision." For melanoma, this means the 100% begins as of the date of pathological diagnosis, not the date of the VA claim — retroactive to diagnosis if the claim is filed promptly.

The 100% Rating During Active Treatment

The 100% active treatment rating for melanoma covers all primary treatment modalities:

• Surgical excision — wide local excision, sentinel lymph node biopsy, and lymph node dissection all qualify as active treatment
• Immunotherapy — checkpoint inhibitors such as pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), and combination regimens are active treatment and maintain the 100% rating for the duration
• Targeted therapy — BRAF inhibitors (dabrafenib, vemurafenib) and MEK inhibitors (trametinib, cobimetinib) for BRAF-mutant melanoma are active treatment
• Radiation therapy — used for adjuvant treatment, brain metastases, or palliative care, qualifies as active treatment
• Chemotherapy — less common for melanoma in the modern era but still qualifies
• Clinical trial participation — enrollment in a cancer clinical trial is generally considered active treatment

For Stage IV metastatic melanoma, treatment is typically ongoing or maintained indefinitely, meaning the 100% rating continues. Melanoma patients with brain metastases, visceral spread, or other distant metastases should expect the 100% rating to remain in place for the duration of treatment, which may be the rest of their lives if treatment is continuous.

Rating Residuals After Treatment Ends

Six months after the successful cessation of treatment, VA will schedule a rating review under 38 CFR § 3.105(e). At that point, VA re-rates the veteran based on any remaining residual disabilities from the melanoma or its treatment. For melanoma, common residuals include:

Surgical Scars and Disfigurement

Wide local excision of melanoma — particularly on the face, scalp, neck, or extremities — can result in significant scarring. VA rates scars under:

Lymphedema After Lymph Node Dissection

Sentinel lymph node biopsy and particularly complete lymph node dissection can cause lymphedema — chronic swelling of the affected extremity. VA rates lymphedema under DC 7199 (analogous to DC 6820, lymphangitis) or directly under applicable peripheral nerve codes if the lymph node dissection also disrupted nerve function. Lymphedema in an extremity is rated based on severity and functional impact.

Peripheral Neuropathy from Treatment

Immunotherapy and targeted therapy for melanoma can cause peripheral neuropathy. VA rates treatment-induced neuropathy under the appropriate peripheral nerve codes (8510-8599) based on the specific nerves affected and severity of functional loss.

Continuation of 100% for Recurrence or Metastasis

If melanoma recurs after initial treatment, or if metastatic disease develops, the 100% rating continues. Veterans who experience recurrence should notify VA and update their claims immediately to ensure the 100% rating is restored or maintained without a gap.

Documentation and Evidence for Your Melanoma Claim

Medical Records You Need

• Pathology report confirming melanoma diagnosis (the gold standard; includes stage, Breslow thickness, Clark level, and any sentinel node findings)
• Dermatology and oncology treatment records documenting all treatment received or scheduled
• Imaging studies (PET scan, CT, MRI) showing extent of disease if metastatic
• Surgical reports for excision and any lymph node dissection
• Immunotherapy infusion records if undergoing adjuvant or systemic treatment
• Nexus letter (for direct service connection cases — not needed for PACT Act presumptive)

Service Records You Need

• DD-214 confirming service dates and discharge characterization
• Deployment orders or personnel records confirming service in covered locations (for PACT Act presumptive)
• MOS documentation (for direct service connection via UV exposure)
• Any in-service medical records mentioning skin conditions, burns, or dermatological complaints
• Campaign medals confirming deployment to covered locations

Filing Strategy and Practical Tips

File Immediately Upon Diagnosis

The effective date for your 100% rating under DC 7833 is the date of your histologic (pathology) diagnosis — not the date you file the claim — as long as you file within one year of diagnosis. Do not wait. File your VA disability claim as soon as you receive your melanoma diagnosis. Every month of delay potentially costs you retroactive compensation.

Assert Both Pathways If Eligible

If your service dates and locations qualify for the PACT Act presumptive, assert it. But also preserve the direct service connection argument in case VA denies the presumptive. Filing both pathways simultaneously — PACT Act presumptive AND direct service connection via UV exposure — gives you two bites at the apple without any additional cost or filing complexity.

File for All Residuals Proactively

Don't wait for VA to tell you what to claim after treatment. Before your six-month re-evaluation, file separate claims for every residual: scars (DC 7800-7805), lymphedema, peripheral neuropathy from treatment, any dermatological sequelae. Filing proactively ensures you don't miss the effective date window.

Related Claims to Consider

Veterans with melanoma should evaluate whether secondary claims are warranted:

• Mental health conditions secondary to melanoma — PTSD, major depression, and anxiety disorders secondary to a life-threatening cancer diagnosis are ratable under 38 CFR § 3.310
• Sleep disturbance secondary to melanoma or treatment — treatment side effects commonly disrupt sleep; a secondary claim for sleep apnea or insomnia may be appropriate
• Other skin conditions — if treatment for melanoma has caused other dermatological conditions (drug-induced rash, photosensitivity, etc.), these may qualify as secondary

For more information on PACT Act presumptive conditions broadly, see our guide on PACT Act presumptive conditions and our burn pit exposure VA claims resource. Veterans pursuing other cancer claims may also find our guides on lung cancer VA claims under the PACT Act and bladder cancer VA disability claims useful.